EGFR and non-small cell lung carcinoma: Nearly 30%–50% of the NSCLC patients progressed to brain metastasis following the preliminary diagnosis or after the anti-tumor treatment (5); even with whole brain radiation therapy (WBRT), stereotactic radiation therapy (SRT), and postoperation or epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), many patients still have a poor prognosis (4–7).